New potential therapeutic modalities: Antithrombin III

Sepsis

Volumn 3, Issue 2, 1999, Pages 153-159

  Opal, Steven M ^a   Thijs, Lambert G ^b  

^a BROWN UNIVERSITY   (United States)

^b NONE

Author keywords

Anticoagulation; Antithrombin III; Coagulation; Sepsis; Septic shock

Indexed keywords

ANTITHROMBIN III;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACTIVITY; HUMAN; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN STRUCTURE; SEPSIS; SEPTIC SHOCK;

EID: 0033509816     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009807718168     Document Type: Article

References (56)

1. Asaka S, Shibayama Y, Nakata K. Pathogenesis of focal and random hepatocellular necrosis in endotoxemia: Microscopic observation in vivo. Liver 1996;16:183-187.
2. Gando S, Kamene T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemostas 1996;75:224-228.
3. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemostas 1998;24:33-44.
4. Lorente JA, García-Frade LJ, Landín L, dePablo R, Torrado C, Renes E, Garcí-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-1542.
5. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979.
6. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxin in humans: An analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1996;88:2520-2528.
7. Carvalho AC, Freeman NJ. How coagulation defects alter the outcome of sepsis: Survival may depend on reversing the procoagulant conditions. J Crit Illness 1994;9:51-75.
8. Hinshaw LB. Sepsis/septic shock: Participation of the microcirculation - An abbreviated review. Crit Care Med 1996;24:1072-1078.
9. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Haemostas 1998;24:61-69.
10. Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Haemostas 1998;24:71-80.
11. Taylor FB Jr., Chang A, Ruf W, Morrissey JH, Hinshaw L, Katlett R, Blick K, Edgington TS. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-135.
12. Gando S, Smanzaki S, Sasaki S, Aoi K, Kemmotsu O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998;26: 2005-2009.
13. Gray E, Thomas S, Mistry Y, Poole S. Inhibition of tissue factor and cytokine release. Haemostasis 1996;26:92-95.
14. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB, Colman RW. The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 1993;91: 61-70.
15. van der Poll T, Jansen PW, van Zee KJ, Lolborn MB, deJong I, Hack CE, Loetscher H, Lasslauer W, Lowry SF, Moldawer LL. Tumor necrosis factor-α induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996;88:922-927.
16. Quick AJ. The normal antithrombin of the blood and its relationship to heparin. Am J Physiol 1938;123:712-719.
17. Mannen EF. Antithrombin III: Its physiologic importance and role in DIC. Semin Thromb Haemostas 1998;24:19-25.
18. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1 q 23-25. Cytogenet Cell Genet 1985;39:67-74.
19. Jagd S, Vibe-Petersen K, Magnussen S. Location of two of the introns of in the antithrombin-III gene. FEBS Lett 1985; 193:213-218.
20. Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985;260:610-619.
21. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor. Blood 1996;15:2301-2307.
22. Hamamoto T, Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1996;7: 470-476.
23. Carrell RW, Boswell DR. Serpins: The superfamily of plasma serine proteinase inhibitors. In: Barrett AJ, Salveson G, eds. Proteinase Inhibitors. Amsterdam, The Netherlands: Elsevier, 1986:403-420.
24. Murano G, Williams L, Miller-Andersson MX, Aronson DL, King C. Some properties of antithrombin-III and its concentrations in human plasma. Thromb Res 1980;18:259-262.
25. Mammen EF. Clinical relevance of antithrombin deficiencies. Semin Hematol 1995;4(Suppl 2):2-6.
26. Fresbelius S, Hedin U, Swedenborg J. Thrombogenicity of the injured vessel wall, role of antithrombin and heparin. Thromb Haemostas 1994;71:147-153.
27. Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissues. Biochemistry 1984;23:1730-1737.
28. Laberrere CA, Faulk WP. Antithrombin determinants of coronary artery disease in transplanted human hearts. Semin Hematol 1995;32(Suppl 2):61-66.
29. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;163:1404-1411.
30. Horie S, Ichii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:899-904.
31. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (AT III) and TRP49-modified AT III on plasma level of 6-Keto-PGF1 ∝ in rats. Thromb Res 1995;80:201-208.
32. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270:L921-L930.
33. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Tromb Res 1998;89:233-241.
34. Harada N., Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93:157-164.
35. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997;96: 2302-2310.
36. Inthorn D, Hoffmann JN, Harti WH, Mühlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998;10:90-96.
37. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823.
38. Masters RW, Mannucci PW, Coppola R, Keller T, Ostermann H, Kienast J. Factor VII and antithrombin III activity during sepsis and septic shock in neutropenic patients. Blood 1996;88:881-886.
39. Uchiba M, Okajima K. Antithrombin III prevents LPS-induced vascular injury: Novel biological activity of antithrombin III. Semin Thromb Haemostas 1997;23:583-590.
40. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999;27:597-604.
41. Wolbink G-J, Bossink AWJ, Groeneveld ABJ, DeGroot MCM, Thijs LG, Hack CE. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis 1998;177:81-87.
42. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood 1996;88:3259-3287.
43. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW. P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia. J Exp Med 1994;179:329-334.
44. Lim YC, Snapp K, Kansas GS, Camphaysen R, Ding H, Luscinskas FW. Important contributions of P-selectin glycoprotein ligand-1-mediated secondary capture of human monocyte adhesin to P-selectin, E-selectin, and TNF-alpha-activated endothelium under flow in vitro. J Immunol 1998;161:2501-2508.
45. Borges E, Eytner R, Moll T, et al. The P-selectin glycoprotein ligand-1 is important for recruitment of neutrophils into inflamed mouse peritoneum. Blood 1997;90:1934-1942.
46. Malhotra R, Priest R, Foster MR, Brad MI. P-selectin binds to bacterial lipopolysaccharide. Eur J Immunol 1998;28: 985-988.
47. Mann LT, Jensenius JC, Simonsen M, Abilgaard U. Antithrombin III: Protection against death after injection of thromboplastin. Science 1969;166:517-518.
48. Dellinger P, Opal SM, Rotrosen D, Sufferdini AF, Zimmerman J. NIH conference: The future of sepsis research: From the bench to the bedside. Chest 1997;111:744-753.
49. Opal SM. Lessons learned from recent clinical trials for sepsis. J Endotoxin Res 1995;2:221-226.
50. Piper RD. Cook DJ, Bone RC, Sibbald WJ. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996;24:2059-2070.
51. Eisele B, Lamy M, Thijs LG, Keinecke H-O, Schuster H-P, Matthias Fr, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis: A randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized-placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-672.
52. Balk R, Emerson T, Fourrier F, Kruse J, Mammen E, Schuster H-P, Vinazzer H. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Haemostas 1998;24(2):183-194.
53. Schipper HG, Jenkins CSP, Kahl LH, Ten Cate JW. Antithrombin III transfusion in disseminated intravascular coagulation. Lancet 1978;I:854-856.
54. Inthorn D, Hoffmann JM, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997;8: 328-334.
55. Fourrier F, Chopin C, Huart J-J, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888.
56. Baudo F, Caimi TM, deCataldo F, et al. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or post surgical complications: A double-blind, randomized, multicenter trial. Intensive Care Med 1998;24:336-342.